Why is the FDA increasing unannounced inspections at foreign facilities?

The FDA announced an expanded program of unannounced inspections at foreign manufacturing sites in May 2025. The move is driven by (1) growing reliance on overseas manufacturing for drugs, biologics, and food; (2) persistent data-integrity and cGMP problems found more often in foreign inspections; (3) the need to prevent concealment of violations that advanced notice can enable; (4) new policy signals (including executive direction and user-fee changes) and (5) technology that helps the agency identify higher-risk targets faster (for example, the agency's new AI assistant, Elsa). The shift also reflects long-standing staffing, resource, and coordination challenges. The FDA is increasing risk-based, unannounced activity while also relying more on tech and foreign regulatory partners. Practical consequence for pharma and medical device firms: be inspection-ready at all times, tighten data integrity and supply-chain documentation, and treat unannounced inspections as a realistic, near-term regulatory risk. This information is sourced from the Atlas Compliance tool. For more details, visit their website.

Background: inspection landscape and what changed recently

Over the past decade, the FDA has shifted to a more global inspection posture because an increasing share of drugs, APIs, biologics, and high-volume food items consumed in the U.S. are manufactured outside the country. FDA's foreign inspection program has expanded substantially since the COVID-19 pause in inspections, but capacity and tools have not scaled evenly with the growth in foreign manufacturing. In May 2025, the FDA formally announced plans to expand its use of unannounced inspections at foreign manufacturing facilities that make essential medicines, foods, and medical products for U.S. consumers, a step intended to better match domestic and foreign inspection practices and reduce the chance that problems are hidden before investigators arrive.

Primary drivers for the policy change

Below are the most important reasons the FDA is leaning into more unannounced foreign inspections.

1 Globalized supply chains and concentrated risks

Pharmaceutical supply chains have become more global and concentrated in particular countries and regions for APIs and finished dose manufacturing. When many products depend on a handful of foreign sites, any quality lapse there can have a national impact (shortages, recalls, patient harm). Unannounced inspections reduce time for corrective staging and provide a more realistic snapshot of daily operations. Regulatory action, therefore, becomes more preventative than reactive.

2 Evidence of worse findings and data integrity concerns abroad

FDA and independent oversight reports have shown that serious cGMP and data-integrity issues are identified in a notable portion of foreign inspections. These include manipulated records, incomplete batch documentation, and test results outside validated ranges that were not investigated properly. The agency's decision to increase unannounced visits is tied directly to the need to observe "the way they actually work" rather than an idealized, pre-arranged version of operations. Recent oversight reports and FDA inspection summaries emphasize these recurring problems.

3 Preventing concealment and equating oversight (no advanced notice)

When firms get advanced notice, they can temporarily correct visible noncompliances, move inventory offsite, or prepare documents that do not reflect routine practice. Unannounced inspections reduce this "clean up before the investigator arrives" problem, making it harder to conceal poor practices and increasing the chance of early detection of systemic issues. FDA's May 6, 2025 announcement explicitly framed the expanded approach around preventing concealment and improving public protection.

4 Political and policy signals: executive direction and fees

Regulatory posture changes do not occur in a vacuum. In 2025, there were clear policy directions pushing for stronger oversight of foreign suppliers, including executive branch actions and related guidance that emphasized inspection frequency and user-fee changes to provide resources for more enforcement and oversight. Those policy signals accelerate and legitimize operational shifts at the FDA.

5 Technology and targeted risk-based inspection (AI + data)

The FDA has rolled out new digital tools to help prioritize inspections and accelerate evidence review. One prominent addition is Elsa, the agency's internal generative-AI assistant, which the FDA says can help summarize safety data, speed reviews, and target inspections more precisely. While AI is an accelerant (it does not replace human judgment), it helps the FDA sift large datasets, adverse events, import refusals, past inspection outcomes, and focus scarce in-person resources on where risk looks highest. Combining risk analytics with a willingness to go unannounced increases the chance of catching noncompliance that previously escaped notice.

6 Oversight and workforce realities

Paradoxically, the FDA has faced investigator vacancies and workforce constraints even as its overseas inspection role grew. GAO and other oversight bodies have repeatedly recommended strategies to retain and scale the FDA's inspection workforce, improve training, and modernize tools. Doing more unannounced inspections is not cost-free: it requires travel, embassy coordination, logistics, and local legal awareness. The policy change is therefore a balancing act, using smarter targeting and foreign cooperation to maximize impact despite staffing limits.

What the agency specifically said (May 2025 announcement)

On May 6, 2025, the FDA announced its intent to expand unannounced inspections at foreign manufacturing sites that produce foods, essential medicines, and other medical products for U.S. patients. The agency framed the change as an effort to:

• reduce the opportunity for concealment of problems that advance notice enables;
• ensure consistent standards between domestic and foreign oversight;
• Use risk-targeted approaches to inspect facilities that pose a higher potential harm to Americans.

The public statement is explicit: the safety of the U.S. supply requires more realistic, on-the-ground evaluations, including unannounced visits where the law and logistics permit. The agency also noted it will continue to work with foreign regulatory partners and use mutual recognition where appropriate, while strengthening direct inspection coverage where needed.

The investigator angle: who does these inspections, and what's different now?

When people say "investigators," they mean FDA investigators and field staff within the Office of Regulatory Affairs (ORA) and center-specific investigators (CDER, CBER, CDRH). Key points about the investigator workforce and how it matters for unannounced foreign inspections:

1 Investigator staffing and retention challenges

The Government Accountability Office (GAO) has documented vacancies in drug investigator positions and recommended FDA adopt workforce retention strategies. If the agency lacks investigators, it must prioritize inspections, which is where AI targeting and unannounced inspections intersect: focused visits to high-risk facilities yield more safety benefit per investigator day. But the logistics of rapid, unannounced overseas deployment remain challenging (visas, bilateral coordination, travel safety).

2 Training and inspection modernization

Investigators receive training in cGMP, data integrity audits, and, increasingly, remote tools (records review platforms, sample-tracking, remote video witnessing). Unannounced foreign inspections place a premium on field judgment: investigators must collect near-real-time samples, secure electronic records, and assess whether practices are habitual. The rollout of Elsa and other digital tools supports investigators by rapidly summarizing evidence and flagging anomalies for deeper investigation.

3 Coordination with foreign offices and mutual recognition

The FDA operates foreign offices and works with counterpart regulators. Where mutual recognition agreements (MRAs) exist, the FDA may rely on partner inspection reports; where they don't, the FDA must perform its own work. Unannounced inspections complicate diplomatic coordination but are used where the FDA judges risk justifies direct action. Investigators, therefore, increasingly operate in a mixed environment: bilateral agreement plus targeted independent activity.

Evidence and numbers: what the data show

Below are the key datapoints and trend indicators that shaped this policy, summaries of public reports, and inspection and enforcement data.

• FY2023 inspection levels: After pandemic disruptions, the FDA resumed foreign inspections and reported hundreds of foreign visits in FY2023. But foreign inspection numbers remain below pre-pandemic levels, leading to a backlog of oversight needs. (See FDA FY2023 inspection report.)
• GAO findings on workforce: GAO's November 2024 report documented investigator vacancies and urged the FDA to implement strategies to retain and better deploy its workforce. GAO flagged the need for alternative inspection tools and improved workforce data to support foreign inspection planning.
• Recent enforcement anecdotes and recalls: High-profile recalls and outbreaks tied to foreign sources (food or drugs) in recent years have increased pressure on the FDA to detect problems earlier and reduce dependence on post-market signals. News coverage of outbreaks and enforcement actions contributed to the urgency of stronger foreign oversight.
• Agency announcements: FDA's May 6, 2025, press release, the formal statement expanding unannounced inspections, is the primary policy document announcing the shift. It explicitly links the change to consumer protection and consistent standards.

Atlas

See what the FDA knows about your next investigator.

30 minutes with the founder. No pitch deck.

See it live

What this means operationally for foreign manufacturers and supply chains

Here's a practical breakdown for people working in pharma manufacturing, quality, and regulatory affairs.

1 Expect inspections with little or no advance notice

Plan for inspections as if they can occur any day. That means:

• Maintain audit-ready documentation every day (raw data, LIMS/ELN audit trails, batch records).
• Ensure batch release decisions, deviations, and investigations are complete and evidence-based.
• Keep key personnel reachable and trained on inspection interactions, including translation and local liaison processes.

2 Data integrity becomes front and center

Because unannounced inspections let investigators look at "living" electronic and paper records, lapses in data integrity (missing metadata, overwritten records, unexplained gaps) will be a major focus. Firms must:

• Harden electronic systems (proper user access, audit trails, validated systems).
• Keep paper backup processes consistent and auditable.
• Implement routine internal surveillance (data-integrity spot checks).

3 Strengthen internal audit and continuous monitoring

Rather than an annual readiness push, firms will need continuous quality-system health checks:

• Conduct unscheduled internal audits to simulate unannounced visits.
• Use third-party audits, but ensure they are risk-based and competent.
• Monitor product complaints, stability data, and trending to catch systemic problems before investigators do.

4 Prepare for investigator logistics and sampling

Investigators may collect samples on site. Ensure chain-of-custody, sample storage, and analytical method readiness. Be ready to provide secure access to batch testing data and stability results.

Risks, trade-offs, and likely next steps for the FDA

Expanding unannounced foreign inspections improves the chance of finding real day-to-day issues, but it also has trade-offs:

• Resource intensity: Unannounced foreign inspections cost more per visit (travel, diplomatic clearance, on-site logistics). FDA will need to carefully target the highest-risk facilities to preserve resource efficiency. GAO has already pushed for workforce improvements and better retention to sustain any expansion.
• Diplomatic and legal constraints: Not every country accepts truly unannounced inspections. The agency must balance sovereign sensitivities and bilateral trust with public-health obligations. Where MRAs exist, the FDA may continue to rely on partner reports instead of independent unannounced visits.
• Industry burden and compliance costs: For honest manufacturers, the burden is to be inspection-ready daily. For those who previously relied on "clean-up before inspection," the capacity to mask issues will shrink, leading to more findings and possibly enforcement. Expect a short-term spike in 483s or warning letters being issued from foreign inspections as the program scales.
• Technology will play a growing role: AI and data analytics (for example, Elsa) will be used to refine targeting and to manage inspection workloads. This should improve the ROI of inspections but also raise questions about algorithmic transparency, error rates, and the need for human oversight in risk classification.

Practical checklist: how to get ready

Below is a pragmatic checklist for manufacturers, quality leads, and supply-chain teams.

People & culture

• Train staff on unannounced inspection procedures and mock interviews.
• Maintain an on-call roster for QA, QA-Release, QC, and technical SMEs.

Documentation & data

• Keep complete, time-stamped records (electronic and paper) accessible.
• Validate and protect LIMS/ELN systems; confirm audit trails are intact.
• Record all deviations, CAPAs, and investigations with root-cause evidence.

Manufacturing & controls

• Ensure batch records are complete and accurate for ongoing, recent, and shipped batches.
• Maintain cleaning, environmental monitoring, and sampling logs in near-real-time.

Suppliers & supply chain

• Verify raw-material traceability and supplier audit status.
• Keep certificates of analysis (CoAs) and supplier investigation files current.

Regulatory & legal

• Maintain counsel/liaison for local legal issues (entry refusals, consular processes).
• Prepare a comprehensive inspection response package and designate spokespeople.

What to watch next

If you follow this topic, watch for these indicators that show how the program will evolve:

1. Inspection outcome trends. Watch FDA inspection summaries and enforcement letters for frequency and severity of foreign inspection findings.
2. GAO or congressional follow-up. GAO will likely continue to report on staffing and program effectiveness; congressional hearings could shape funding.
3. Elsa and tech governance. How FDA documents Elsa's role in inspection targeting and what validation/oversight mechanisms are put around AI decisions.
4. Bilateral/regulatory cooperation. Mutual recognition expansion or new MOUs could change where the FDA directs unannounced inspections vs. where it relies on partners.